Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carya ovata pollen is a non-standardized allergenic extract derived from the pollen of the Carya ovata plant, commonly known as the shagbark hickory tree. [9, 11] It is classified as an allergenic biologic and is primarily used for the diagnosis of immediate hypersensitivity allergies to shagbark hickory pollen. [3, 7] Administration is performed by physicians via percutaneous, intradermal, or subcutaneous routes for skin testing. [7] The extract can also be used for immunotherapy to reduce allergen-induced symptoms in sensitized individuals. [7] The active ingredient is the pollen extract, which elicits a localized Type I hypersensitivity reaction in allergic patients, confirming sensitization. It is distributed by companies specializing in allergy solutions, such as ALK-Abello and Stallergenes Greer. [12, 13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carya ovata pollen.